Literature DB >> 21131692

Lipid-lowering effect of tenofovir in HIV-infected patients.

Massimiliano Fabbiani, Laura Bracciale, Maria Doino, Letizia Sidella, Salvatore Farina, Valentina Di Cristo, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21131692     DOI： 10.1093/jac/dkq464

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  7 in total

1.  Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.

Authors:  Mitch M Matoga; Mina C Hosseinipour; Evgenia Aga; Heather J Ribaudo; Nagalingeswaran Kumarasamy; John Bartlett; Michael D Hughes
Journal:  Antivir Ther       Date:  2016-10-14

2.  Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.

Authors:  Sara Jeong; Hyun Phil Shin; Ha Il Kim
Journal:  Intervirology       Date:  2021-11-03       Impact factor: 2.294

3.  Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.

Authors:  Hirotaka Arae; Masao Tateyama; Hideta Nakamura; Daisuke Tasato; Kaoru Kami; Kyoko Miyagi; Saori Maeda; Hitoshi Uehara; Makiko Moromi; Katsunori Nakamura; Jiro Fujita
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

4.  Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.

Authors:  Andrea Giacomelli; Alice Ranzani; Letizia Oreni; Elena Gervasi; Angelica Lupo; Anna Lisa Ridolfo; Massimo Galli; Stefano Rusconi
Journal:  Drug Des Devel Ther       Date:  2019-07-09       Impact factor: 4.162

5.  Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.

Authors:  Gregory D Huhn; David J Shamblaw; Jean-Guy Baril; Priscilla Y Hsue; Brittany L Mills; Thai Nguyen-Cleary; Scott McCallister; Moupali Das
Journal:  Open Forum Infect Dis       Date:  2019-11-11       Impact factor: 3.835

6.  Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.

Authors:  Andrea Giacomelli; Federico Conti; Laura Pezzati; Letizia Oreni; Anna Lisa Ridolfo; Valentina Morena; Cecilia Bonazzetti; Gabriele Pagani; Tiziana Formenti; Massimo Galli; Stefano Rusconi
Journal:  BMC Infect Dis       Date:  2021-06-22       Impact factor: 3.090

Review 7.  Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review.

Authors:  Mariusz Sapuła; Magdalena Suchacz; Andrzej Załęski; Alicja Wiercińska-Drapało
Journal:  Viruses       Date:  2022-01-11       Impact factor: 5.048
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.